GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Total Current Liabilities

Actelion (Actelion) Total Current Liabilities : $522 Mil (As of Mar. 2017)


View and export this data going back to . Start your Free Trial

What is Actelion Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Actelion's total current liabilities for the quarter that ended in Mar. 2017 was $522


Actelion Total Current Liabilities Historical Data

The historical data trend for Actelion's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Total Current Liabilities Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 499.39 1,088.11 681.42 423.06 558.12

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 434.87 481.82 518.26 558.12 522.39

Actelion Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Actelion's Total Current Liabilities for the fiscal year that ended in Dec. 2016 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=113.921+0
+Other Current Liabilities+Current Deferred Liabilities
=444.201+0
=558

Actelion's Total Current Liabilities for the quarter that ended in Mar. 2017 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=97.904+0
+Other Current Liabilities+Current Deferred Liabilities
=424.488+0
=522

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Actelion Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Actelion's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Actelion (Actelion) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson 08-03-2016

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 02-14-2017

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 01-24-2017

Actelion Still On Growth Track

By reports.droy reports.droy 02-18-2015